1 Market Overview

1.1 Product Overview and Scope of Targeted Drug EGFR RTK Inhibitors for NSCLC

1.2 Classification of Targeted Drug EGFR RTK Inhibitors for NSCLC by Type

1.2.1 Overview: Global Targeted Drug EGFR RTK Inhibitors for NSCLC Market Size by Type: 2020 Versus 2021 Versus 2026

1.2.2 Global Targeted Drug EGFR RTK Inhibitors for NSCLC Revenue Market Share by Type in 2020

1.2.3 Icotinib

1.2.4 Gefitinib

1.2.5 Erlotinib

1.2.6 Afatinib

1.2.7 Osimertinib

1.2.8 Brigatinib

1.2.9 Other

1.3 Global Targeted Drug EGFR RTK Inhibitors for NSCLC Market by Application

1.3.1 Overview: Global Targeted Drug EGFR RTK Inhibitors for NSCLC Market Size by Application: 2020 Versus 2021 Versus 2026

1.3.2 Squamous Cell Carcinoma of NSCLC

1.3.3 Adenocarcinoma of NSCLC

1.3.4 Large Cell Carcinoma of NSCLC

1.4 Global Targeted Drug EGFR RTK Inhibitors for NSCLC Market Size & Forecast

1.5 Global Targeted Drug EGFR RTK Inhibitors for NSCLC Market Size and Forecast by Region

1.5.1 Global Targeted Drug EGFR RTK Inhibitors for NSCLC Market Size by Region: 2016 VS 2021 VS 2026

1.5.2 Global Targeted Drug EGFR RTK Inhibitors for NSCLC Market Size by Region, (2016-2021)

1.5.3 North America Targeted Drug EGFR RTK Inhibitors for NSCLC Market Size and Prospect (2016-2026)

1.5.4 Europe Targeted Drug EGFR RTK Inhibitors for NSCLC Market Size and Prospect (2016-2026)

1.5.5 Asia-Pacific Targeted Drug EGFR RTK Inhibitors for NSCLC Market Size and Prospect (2016-2026)

1.5.6 South America Targeted Drug EGFR RTK Inhibitors for NSCLC Market Size and Prospect (2016-2026)

1.5.7 Middle East and Africa Targeted Drug EGFR RTK Inhibitors for NSCLC Market Size and Prospect (2016-2026)

1.6 Market Drivers, Restraints and Trends

1.6.1 Targeted Drug EGFR RTK Inhibitors for NSCLC Market Drivers

1.6.2 Targeted Drug EGFR RTK Inhibitors for NSCLC Market Restraints

1.6.3 Targeted Drug EGFR RTK Inhibitors for NSCLC Trends Analysis

2 Company Profiles

2.1 Beta Pharma

2.1.1 Beta Pharma Details

2.1.2 Beta Pharma Major Business

2.1.3 Beta Pharma Targeted Drug EGFR RTK Inhibitors for NSCLC Product and Solutions

2.1.4 Beta Pharma Targeted Drug EGFR RTK Inhibitors for NSCLC Revenue, Gross Margin and Market Share (2019-2021)

2.1.5 Beta Pharma Recent Developments and Future Plans

2.2 AstraZeneca

2.2.1 AstraZeneca Details

2.2.2 AstraZeneca Major Business

2.2.3 AstraZeneca Targeted Drug EGFR RTK Inhibitors for NSCLC Product and Solutions

2.2.4 AstraZeneca Targeted Drug EGFR RTK Inhibitors for NSCLC Revenue, Gross Margin and Market Share (2019-2021)

2.2.5 AstraZeneca Recent Developments and Future Plans

2.3 Natco Pharma

2.3.1 Natco Pharma Details

2.3.2 Natco Pharma Major Business

2.3.3 Natco Pharma Targeted Drug EGFR RTK Inhibitors for NSCLC Product and Solutions

2.3.4 Natco Pharma Targeted Drug EGFR RTK Inhibitors for NSCLC Revenue, Gross Margin and Market Share (2019-2021)

2.3.5 Natco Pharma Recent Developments and Future Plans

2.4 Qilu Pharmaceutical

2.4.1 Qilu Pharmaceutical Details

2.4.2 Qilu Pharmaceutical Major Business

2.4.3 Qilu Pharmaceutical Targeted Drug EGFR RTK Inhibitors for NSCLC Product and Solutions

2.4.4 Qilu Pharmaceutical Targeted Drug EGFR RTK Inhibitors for NSCLC Revenue, Gross Margin and Market Share (2019-2021)

2.4.5 Qilu Pharmaceutical Recent Developments and Future Plans

2.5 Genentech (Roche Group)

2.5.1 Genentech (Roche Group) Details

2.5.2 Genentech (Roche Group) Major Business

2.5.3 Genentech (Roche Group) Targeted Drug EGFR RTK Inhibitors for NSCLC Product and Solutions

2.5.4 Genentech (Roche Group) Targeted Drug EGFR RTK Inhibitors for NSCLC Revenue, Gross Margin and Market Share (2019-2021)

2.5.5 Genentech (Roche Group) Recent Developments and Future Plans

2.6 Mylan

2.6.1 Mylan Details

2.6.2 Mylan Major Business

2.6.3 Mylan Targeted Drug EGFR RTK Inhibitors for NSCLC Product and Solutions

2.6.4 Mylan Targeted Drug EGFR RTK Inhibitors for NSCLC Revenue, Gross Margin and Market Share (2019-2021)

2.6.5 Mylan Recent Developments and Future Plans

2.7 Teva

2.7.1 Teva Details

2.7.2 Teva Major Business

2.7.3 Teva Targeted Drug EGFR RTK Inhibitors for NSCLC Product and Solutions

2.7.4 Teva Targeted Drug EGFR RTK Inhibitors for NSCLC Revenue, Gross Margin and Market Share (2019-2021)

2.7.5 Teva Recent Developments and Future Plans

2.8 OSI Pharmaceuticals

2.8.1 OSI Pharmaceuticals Details

2.8.2 OSI Pharmaceuticals Major Business

2.8.3 OSI Pharmaceuticals Targeted Drug EGFR RTK Inhibitors for NSCLC Product and Solutions

2.8.4 OSI Pharmaceuticals Targeted Drug EGFR RTK Inhibitors for NSCLC Revenue, Gross Margin and Market Share (2019-2021)

2.8.5 OSI Pharmaceuticals Recent Developments and Future Plans

2.9 Glenmark Pharmaceuticals

2.9.1 Glenmark Pharmaceuticals Details

2.9.2 Glenmark Pharmaceuticals Major Business

2.9.3 Glenmark Pharmaceuticals Targeted Drug EGFR RTK Inhibitors for NSCLC Product and Solutions

2.9.4 Glenmark Pharmaceuticals Targeted Drug EGFR RTK Inhibitors for NSCLC Revenue, Gross Margin and Market Share (2019-2021)

2.9.5 Glenmark Pharmaceuticals Recent Developments and Future Plans

2.10 Beacon Pharmaceuticals

2.10.1 Beacon Pharmaceuticals Details

2.10.2 Beacon Pharmaceuticals Major Business

2.10.3 Beacon Pharmaceuticals Targeted Drug EGFR RTK Inhibitors for NSCLC Product and Solutions

2.10.4 Beacon Pharmaceuticals Targeted Drug EGFR RTK Inhibitors for NSCLC Revenue, Gross Margin and Market Share (2019-2021)

2.10.5 Beacon Pharmaceuticals Recent Developments and Future Plans

2.11 Boehringer Ingelheim

2.11.1 Boehringer Ingelheim Details

2.11.2 Boehringer Ingelheim Major Business

2.11.3 Boehringer Ingelheim Targeted Drug EGFR RTK Inhibitors for NSCLC Product and Solutions

2.11.4 Boehringer Ingelheim Targeted Drug EGFR RTK Inhibitors for NSCLC Revenue, Gross Margin and Market Share (2019-2021)

2.11.5 Boehringer Ingelheim Recent Developments and Future Plans

2.12 Pfizer

2.12.1 Pfizer Details

2.12.2 Pfizer Major Business

2.12.3 Pfizer Targeted Drug EGFR RTK Inhibitors for NSCLC Product and Solutions

2.12.4 Pfizer Targeted Drug EGFR RTK Inhibitors for NSCLC Revenue, Gross Margin and Market Share (2019-2021)

2.12.5 Pfizer Recent Developments and Future Plans

2.13 ARIAD Pharmaceuticals (Takeda)

2.13.1 ARIAD Pharmaceuticals (Takeda) Details

2.13.2 ARIAD Pharmaceuticals (Takeda) Major Business

2.13.3 ARIAD Pharmaceuticals (Takeda) Targeted Drug EGFR RTK Inhibitors for NSCLC Product and Solutions

2.13.4 ARIAD Pharmaceuticals (Takeda) Targeted Drug EGFR RTK Inhibitors for NSCLC Revenue, Gross Margin and Market Share (2019-2021)

2.13.5 ARIAD Pharmaceuticals (Takeda) Recent Developments and Future Plans

2.14 Genvio Pharma Limited

2.14.1 Genvio Pharma Limited Details

2.14.2 Genvio Pharma Limited Major Business

2.14.3 Genvio Pharma Limited Targeted Drug EGFR RTK Inhibitors for NSCLC Product and Solutions

2.14.4 Genvio Pharma Limited Targeted Drug EGFR RTK Inhibitors for NSCLC Revenue, Gross Margin and Market Share (2019-2021)

2.14.5 Genvio Pharma Limited Recent Developments and Future Plans

2.15 Drug International Limted

2.15.1 Drug International Limted Details

2.15.2 Drug International Limted Major Business

2.15.3 Drug International Limted Targeted Drug EGFR RTK Inhibitors for NSCLC Product and Solutions

2.15.4 Drug International Limted Targeted Drug EGFR RTK Inhibitors for NSCLC Revenue, Gross Margin and Market Share (2019-2021)

2.15.5 Drug International Limted Recent Developments and Future Plans

2.16 Everest Pharmaceuticals

2.16.1 Everest Pharmaceuticals Details

2.16.2 Everest Pharmaceuticals Major Business

2.16.3 Everest Pharmaceuticals Targeted Drug EGFR RTK Inhibitors for NSCLC Product and Solutions

2.16.4 Everest Pharmaceuticals Targeted Drug EGFR RTK Inhibitors for NSCLC Revenue, Gross Margin and Market Share (2019-2021)

2.16.5 Everest Pharmaceuticals Recent Developments and Future Plans

2.17 Incepta Pharmaceuticals Limited

2.17.1 Incepta Pharmaceuticals Limited Details

2.17.2 Incepta Pharmaceuticals Limited Major Business

2.17.3 Incepta Pharmaceuticals Limited Targeted Drug EGFR RTK Inhibitors for NSCLC Product and Solutions

2.17.4 Incepta Pharmaceuticals Limited Targeted Drug EGFR RTK Inhibitors for NSCLC Revenue, Gross Margin and Market Share (2019-2021)

2.17.5 Incepta Pharmaceuticals Limited Recent Developments and Future Plans

2.18 Cipla Pharma

2.18.1 Cipla Pharma Details

2.18.2 Cipla Pharma Major Business

2.18.3 Cipla Pharma Targeted Drug EGFR RTK Inhibitors for NSCLC Product and Solutions

2.18.4 Cipla Pharma Targeted Drug EGFR RTK Inhibitors for NSCLC Revenue, Gross Margin and Market Share (2019-2021)

2.18.5 Cipla Pharma Recent Developments and Future Plans

2.19 Dr Reddy's Laboratories

2.19.1 Dr Reddy's Laboratories Details

2.19.2 Dr Reddy's Laboratories Major Business

2.19.3 Dr Reddy's Laboratories Targeted Drug EGFR RTK Inhibitors for NSCLC Product and Solutions

2.19.4 Dr Reddy's Laboratories Targeted Drug EGFR RTK Inhibitors for NSCLC Revenue, Gross Margin and Market Share (2019-2021)

2.19.5 Dr Reddy's Laboratories Recent Developments and Future Plans

2.20 Zydus Cadila

2.20.1 Zydus Cadila Details

2.20.2 Zydus Cadila Major Business

2.20.3 Zydus Cadila Targeted Drug EGFR RTK Inhibitors for NSCLC Product and Solutions

2.20.4 Zydus Cadila Targeted Drug EGFR RTK Inhibitors for NSCLC Revenue, Gross Margin and Market Share (2019-2021)

2.20.5 Zydus Cadila Recent Developments and Future Plans

2.21 Hetero Drugs

2.21.1 Hetero Drugs Details

2.21.2 Hetero Drugs Major Business

2.21.3 Hetero Drugs Targeted Drug EGFR RTK Inhibitors for NSCLC Product and Solutions

2.21.4 Hetero Drugs Targeted Drug EGFR RTK Inhibitors for NSCLC Revenue, Gross Margin and Market Share (2019-2021)

2.21.5 Hetero Drugs Recent Developments and Future Plans

2.22 Intas Pharmaceuticals

2.22.1 Intas Pharmaceuticals Details

2.22.2 Intas Pharmaceuticals Major Business

2.22.3 Intas Pharmaceuticals Targeted Drug EGFR RTK Inhibitors for NSCLC Product and Solutions

2.22.4 Intas Pharmaceuticals Targeted Drug EGFR RTK Inhibitors for NSCLC Revenue, Gross Margin and Market Share (2019-2021)

2.22.5 Intas Pharmaceuticals Recent Developments and Future Plans

2.23 Alkem Laboratories

2.23.1 Alkem Laboratories Details

2.23.2 Alkem Laboratories Major Business

2.23.3 Alkem Laboratories Targeted Drug EGFR RTK Inhibitors for NSCLC Product and Solutions

2.23.4 Alkem Laboratories Targeted Drug EGFR RTK Inhibitors for NSCLC Revenue, Gross Margin and Market Share (2019-2021)

2.23.5 Alkem Laboratories Recent Developments and Future Plans

2.24 RPG Life Sciences

2.24.1 RPG Life Sciences Details

2.24.2 RPG Life Sciences Major Business

2.24.3 RPG Life Sciences Targeted Drug EGFR RTK Inhibitors for NSCLC Product and Solutions

2.24.4 RPG Life Sciences Targeted Drug EGFR RTK Inhibitors for NSCLC Revenue, Gross Margin and Market Share (2019-2021)

2.24.5 RPG Life Sciences Recent Developments and Future Plans

2.25 Fresenius Kabi India

2.25.1 Fresenius Kabi India Details

2.25.2 Fresenius Kabi India Major Business

2.25.3 Fresenius Kabi India Targeted Drug EGFR RTK Inhibitors for NSCLC Product and Solutions

2.25.4 Fresenius Kabi India Targeted Drug EGFR RTK Inhibitors for NSCLC Revenue, Gross Margin and Market Share (2019-2021)

2.25.5 Fresenius Kabi India Recent Developments and Future Plans

3 Market Competition, by Players

3.1 Global Targeted Drug EGFR RTK Inhibitors for NSCLC Revenue and Share by Players (2019-2021)

3.2 Market Concentration Rate

3.2.1 Top 3 Targeted Drug EGFR RTK Inhibitors for NSCLC Players Market Share

3.2.2 Top 10 Targeted Drug EGFR RTK Inhibitors for NSCLC Players Market Share

3.2.3 Market Competition Trend

3.3 Targeted Drug EGFR RTK Inhibitors for NSCLC Players Head Office, Products and Services Provided

3.4 Mergers & Acquisitions

3.5 New Entrants and Expansion Plans

4 Market Size Segment by Type

4.1 Global Targeted Drug EGFR RTK Inhibitors for NSCLC Revenue and Market Share by Type (2016-2021)

4.2 Global Targeted Drug EGFR RTK Inhibitors for NSCLC Market Forecast by Type (2021-2026)

5 Market Size Segment by Application

5.1 Global Targeted Drug EGFR RTK Inhibitors for NSCLC Revenue Market Share by Application (2016-2021)

5.2 Targeted Drug EGFR RTK Inhibitors for NSCLC Market Forecast by Application (2021-2026)

6 North America by Country, by Type, and by Application

6.1 North America Targeted Drug EGFR RTK Inhibitors for NSCLC Revenue by Type (2016-2026)

6.2 North America Targeted Drug EGFR RTK Inhibitors for NSCLC Revenue by Application (2016-2026)

6.3 North America Targeted Drug EGFR RTK Inhibitors for NSCLC Market Size by Country

6.3.1 North America Targeted Drug EGFR RTK Inhibitors for NSCLC Revenue by Country (2016-2026)

6.3.2 United States Targeted Drug EGFR RTK Inhibitors for NSCLC Market Size and Forecast (2016-2026)

6.3.3 Canada Targeted Drug EGFR RTK Inhibitors for NSCLC Market Size and Forecast (2016-2026)

6.3.4 Mexico Targeted Drug EGFR RTK Inhibitors for NSCLC Market Size and Forecast (2016-2026)

7 Europe by Country, by Type, and by Application

7.1 Europe Targeted Drug EGFR RTK Inhibitors for NSCLC Revenue by Type (2016-2026)

7.2 Europe Targeted Drug EGFR RTK Inhibitors for NSCLC Revenue by Application (2016-2026)

7.3 Europe Targeted Drug EGFR RTK Inhibitors for NSCLC Market Size by Country

7.3.1 Europe Targeted Drug EGFR RTK Inhibitors for NSCLC Revenue by Country (2016-2026)

7.3.2 Germany Targeted Drug EGFR RTK Inhibitors for NSCLC Market Size and Forecast (2016-2026)

7.3.3 France Targeted Drug EGFR RTK Inhibitors for NSCLC Market Size and Forecast (2016-2026)

7.3.4 United Kingdom Targeted Drug EGFR RTK Inhibitors for NSCLC Market Size and Forecast (2016-2026)

7.3.5 Russia Targeted Drug EGFR RTK Inhibitors for NSCLC Market Size and Forecast (2016-2026)

7.3.6 Italy Targeted Drug EGFR RTK Inhibitors for NSCLC Market Size and Forecast (2016-2026)

8 Asia-Pacific by Region, by Type, and by Application

8.1 Asia-Pacific Targeted Drug EGFR RTK Inhibitors for NSCLC Revenue by Type (2016-2026)

8.2 Asia-Pacific Targeted Drug EGFR RTK Inhibitors for NSCLC Revenue by Application (2016-2026)

8.3 Asia-Pacific Targeted Drug EGFR RTK Inhibitors for NSCLC Market Size by Region

8.3.1 Asia-Pacific Targeted Drug EGFR RTK Inhibitors for NSCLC Revenue by Region (2016-2026)

8.3.2 China Targeted Drug EGFR RTK Inhibitors for NSCLC Market Size and Forecast (2016-2026)

8.3.3 Japan Targeted Drug EGFR RTK Inhibitors for NSCLC Market Size and Forecast (2016-2026)

8.3.4 South Korea Targeted Drug EGFR RTK Inhibitors for NSCLC Market Size and Forecast (2016-2026)

8.3.5 India Targeted Drug EGFR RTK Inhibitors for NSCLC Market Size and Forecast (2016-2026)

8.3.6 Southeast Asia Targeted Drug EGFR RTK Inhibitors for NSCLC Market Size and Forecast (2016-2026)

8.3.7 Australia Targeted Drug EGFR RTK Inhibitors for NSCLC Market Size and Forecast (2016-2026)

9 South America by Country, by Type, and by Application

9.1 South America Targeted Drug EGFR RTK Inhibitors for NSCLC Revenue by Type (2016-2026)

9.2 South America Targeted Drug EGFR RTK Inhibitors for NSCLC Revenue by Application (2016-2026)

9.3 South America Targeted Drug EGFR RTK Inhibitors for NSCLC Market Size by Country

9.3.1 South America Targeted Drug EGFR RTK Inhibitors for NSCLC Revenue by Country (2016-2026)

9.3.2 Brazil Targeted Drug EGFR RTK Inhibitors for NSCLC Market Size and Forecast (2016-2026)

9.3.3 Argentina Targeted Drug EGFR RTK Inhibitors for NSCLC Market Size and Forecast (2016-2026)

10 Middle East & Africa by Country, by Type, and by Application

10.1 Middle East & Africa Targeted Drug EGFR RTK Inhibitors for NSCLC Revenue by Type (2016-2026)

10.2 Middle East & Africa Targeted Drug EGFR RTK Inhibitors for NSCLC Revenue by Application (2016-2026)

10.3 Middle East & Africa Targeted Drug EGFR RTK Inhibitors for NSCLC Market Size by Country

10.3.1 Middle East & Africa Targeted Drug EGFR RTK Inhibitors for NSCLC Revenue by Country (2016-2026)

10.3.2 Turkey Targeted Drug EGFR RTK Inhibitors for NSCLC Market Size and Forecast (2016-2026)

10.3.3 Saudi Arabia Targeted Drug EGFR RTK Inhibitors for NSCLC Market Size and Forecast (2016-2026)

10.3.4 UAE Targeted Drug EGFR RTK Inhibitors for NSCLC Market Size and Forecast (2016-2026)

11 Research Findings and Conclusion

12 Appendix

12.1 Methodology

12.2 Research Process and Data Source

12.3 Disclaimer

List of Tables

Table 1. Global Targeted Drug EGFR RTK Inhibitors for NSCLC Revenue by Type, (USD Million), 2020 VS 2021 VS 2026

Table 2. Global Targeted Drug EGFR RTK Inhibitors for NSCLC Revenue by Application, (USD Million), 2020 VS 2021 VS 2026

Table 3. Global Market Targeted Drug EGFR RTK Inhibitors for NSCLC Revenue (Million USD) Comparison by Region (2016 VS 2021 VS 2026)

Table 4. Global Targeted Drug EGFR RTK Inhibitors for NSCLC Revenue (USD Million) by Region (2016-2021)

Table 5. Global Targeted Drug EGFR RTK Inhibitors for NSCLC Revenue Market Share by Region (2021-2026)

Table 6. Beta Pharma Corporate Information, Head Office, and Major Competitors

Table 7. Beta Pharma Major Business

Table 8. Beta Pharma Targeted Drug EGFR RTK Inhibitors for NSCLC Product and Solutions

Table 9. Beta Pharma Targeted Drug EGFR RTK Inhibitors for NSCLC Revenue (USD Million), Gross Margin and Market Share (2019-2021)

Table 10. AstraZeneca Corporate Information, Head Office, and Major Competitors

Table 11. AstraZeneca Major Business

Table 12. AstraZeneca Targeted Drug EGFR RTK Inhibitors for NSCLC Product and Solutions

Table 13. AstraZeneca Targeted Drug EGFR RTK Inhibitors for NSCLC Revenue (USD Million), Gross Margin and Market Share (2019-2021)

Table 14. Natco Pharma Corporate Information, Head Office, and Major Competitors

Table 15. Natco Pharma Major Business

Table 16. Natco Pharma Targeted Drug EGFR RTK Inhibitors for NSCLC Product and Solutions

Table 17. Natco Pharma Targeted Drug EGFR RTK Inhibitors for NSCLC Revenue (USD Million), Gross Margin and Market Share (2019-2021)

Table 18. Qilu Pharmaceutical Corporate Information, Head Office, and Major Competitors

Table 19. Qilu Pharmaceutical Major Business

Table 20. Qilu Pharmaceutical Targeted Drug EGFR RTK Inhibitors for NSCLC Product and Solutions

Table 21. Qilu Pharmaceutical Targeted Drug EGFR RTK Inhibitors for NSCLC Revenue (USD Million), Gross Margin and Market Share (2019-2021)

Table 22. Genentech (Roche Group) Corporate Information, Head Office, and Major Competitors

Table 23. Genentech (Roche Group) Major Business

Table 24. Genentech (Roche Group) Targeted Drug EGFR RTK Inhibitors for NSCLC Product and Solutions

Table 25. Genentech (Roche Group) Targeted Drug EGFR RTK Inhibitors for NSCLC Revenue (USD Million), Gross Margin and Market Share (2019-2021)

Table 26. Mylan Corporate Information, Head Office, and Major Competitors

Table 27. Mylan Major Business

Table 28. Mylan Targeted Drug EGFR RTK Inhibitors for NSCLC Product and Solutions

Table 29. Mylan Targeted Drug EGFR RTK Inhibitors for NSCLC Revenue (USD Million), Gross Margin and Market Share (2019-2021)

Table 30. Teva Corporate Information, Head Office, and Major Competitors

Table 31. Teva Major Business

Table 32. Teva Targeted Drug EGFR RTK Inhibitors for NSCLC Product and Solutions

Table 33. Teva Targeted Drug EGFR RTK Inhibitors for NSCLC Revenue (USD Million), Gross Margin and Market Share (2019-2021)

Table 34. OSI Pharmaceuticals Corporate Information, Head Office, and Major Competitors

Table 35. OSI Pharmaceuticals Major Business

Table 36. OSI Pharmaceuticals Targeted Drug EGFR RTK Inhibitors for NSCLC Product and Solutions

Table 37. OSI Pharmaceuticals Targeted Drug EGFR RTK Inhibitors for NSCLC Revenue (USD Million), Gross Margin and Market Share (2019-2021)

Table 38. Glenmark Pharmaceuticals Corporate Information, Head Office, and Major Competitors

Table 39. Glenmark Pharmaceuticals Major Business

Table 40. Glenmark Pharmaceuticals Targeted Drug EGFR RTK Inhibitors for NSCLC Product and Solutions

Table 41. Glenmark Pharmaceuticals Targeted Drug EGFR RTK Inhibitors for NSCLC Revenue (USD Million), Gross Margin and Market Share (2019-2021)

Table 42. Beacon Pharmaceuticals Corporate Information, Head Office, and Major Competitors

Table 43. Beacon Pharmaceuticals Major Business

Table 44. Beacon Pharmaceuticals Targeted Drug EGFR RTK Inhibitors for NSCLC Product and Solutions

Table 45. Beacon Pharmaceuticals Targeted Drug EGFR RTK Inhibitors for NSCLC Revenue (USD Million), Gross Margin and Market Share (2019-2021)

Table 46. Boehringer Ingelheim Corporate Information, Head Office, and Major Competitors

Table 47. Boehringer Ingelheim Major Business

Table 48. Boehringer Ingelheim Targeted Drug EGFR RTK Inhibitors for NSCLC Product and Solutions

Table 49. Boehringer Ingelheim Targeted Drug EGFR RTK Inhibitors for NSCLC Revenue (USD Million), Gross Margin and Market Share (2019-2021)

Table 50. Pfizer Corporate Information, Head Office, and Major Competitors

Table 51. Pfizer Major Business

Table 52. Pfizer Targeted Drug EGFR RTK Inhibitors for NSCLC Product and Solutions

Table 53. Pfizer Targeted Drug EGFR RTK Inhibitors for NSCLC Revenue (USD Million), Gross Margin and Market Share (2019-2021)

Table 54. ARIAD Pharmaceuticals (Takeda) Corporate Information, Head Office, and Major Competitors

Table 55. ARIAD Pharmaceuticals (Takeda) Major Business

Table 56. ARIAD Pharmaceuticals (Takeda) Targeted Drug EGFR RTK Inhibitors for NSCLC Product and Solutions

Table 57. ARIAD Pharmaceuticals (Takeda) Targeted Drug EGFR RTK Inhibitors for NSCLC Revenue (USD Million), Gross Margin and Market Share (2019-2021)

Table 58. Genvio Pharma Limited Corporate Information, Head Office, and Major Competitors

Table 59. Genvio Pharma Limited Major Business

Table 60. Genvio Pharma Limited Targeted Drug EGFR RTK Inhibitors for NSCLC Product and Solutions

Table 61. Genvio Pharma Limited Targeted Drug EGFR RTK Inhibitors for NSCLC Revenue (USD Million), Gross Margin and Market Share (2019-2021)

Table 62. Drug International Limted Corporate Information, Head Office, and Major Competitors

Table 63. Drug International Limted Major Business

Table 64. Drug International Limted Targeted Drug EGFR RTK Inhibitors for NSCLC Product and Solutions

Table 65. Drug International Limted Targeted Drug EGFR RTK Inhibitors for NSCLC Revenue (USD Million), Gross Margin and Market Share (2019-2021)

Table 66. Everest Pharmaceuticals Corporate Information, Head Office, and Major Competitors

Table 67. Everest Pharmaceuticals Major Business

Table 68. Everest Pharmaceuticals Targeted Drug EGFR RTK Inhibitors for NSCLC Product and Solutions

Table 69. Everest Pharmaceuticals Targeted Drug EGFR RTK Inhibitors for NSCLC Revenue (USD Million), Gross Margin and Market Share (2019-2021)

Table 70. Incepta Pharmaceuticals Limited Corporate Information, Head Office, and Major Competitors

Table 71. Incepta Pharmaceuticals Limited Major Business

Table 72. Incepta Pharmaceuticals Limited Targeted Drug EGFR RTK Inhibitors for NSCLC Product and Solutions

Table 73. Incepta Pharmaceuticals Limited Targeted Drug EGFR RTK Inhibitors for NSCLC Revenue (USD Million), Gross Margin and Market Share (2019-2021)

Table 74. Cipla Pharma Corporate Information, Head Office, and Major Competitors

Table 75. Cipla Pharma Major Business

Table 76. Cipla Pharma Targeted Drug EGFR RTK Inhibitors for NSCLC Product and Solutions

Table 77. Cipla Pharma Targeted Drug EGFR RTK Inhibitors for NSCLC Revenue (USD Million), Gross Margin and Market Share (2019-2021)

Table 78. Dr Reddy's Laboratories Corporate Information, Head Office, and Major Competitors

Table 79. Dr Reddy's Laboratories Major Business

Table 80. Dr Reddy's Laboratories Targeted Drug EGFR RTK Inhibitors for NSCLC Product and Solutions

Table 81. Dr Reddy's Laboratories Targeted Drug EGFR RTK Inhibitors for NSCLC Revenue (USD Million), Gross Margin and Market Share (2019-2021)

Table 82. Zydus Cadila Corporate Information, Head Office, and Major Competitors

Table 83. Zydus Cadila Major Business

Table 84. Zydus Cadila Targeted Drug EGFR RTK Inhibitors for NSCLC Product and Solutions

Table 85. Zydus Cadila Targeted Drug EGFR RTK Inhibitors for NSCLC Revenue (USD Million), Gross Margin and Market Share (2019-2021)

Table 86. Hetero Drugs Corporate Information, Head Office, and Major Competitors

Table 87. Hetero Drugs Major Business

Table 88. Hetero Drugs Targeted Drug EGFR RTK Inhibitors for NSCLC Product and Solutions

Table 89. Hetero Drugs Targeted Drug EGFR RTK Inhibitors for NSCLC Revenue (USD Million), Gross Margin and Market Share (2019-2021)

Table 90. Intas Pharmaceuticals Corporate Information, Head Office, and Major Competitors

Table 91. Intas Pharmaceuticals Major Business

Table 92. Intas Pharmaceuticals Targeted Drug EGFR RTK Inhibitors for NSCLC Product and Solutions

Table 93. Intas Pharmaceuticals Targeted Drug EGFR RTK Inhibitors for NSCLC Revenue (USD Million), Gross Margin and Market Share (2019-2021)

Table 94. Alkem Laboratories Corporate Information, Head Office, and Major Competitors

Table 95. Alkem Laboratories Major Business

Table 96. Alkem Laboratories Targeted Drug EGFR RTK Inhibitors for NSCLC Product and Solutions

Table 97. Alkem Laboratories Targeted Drug EGFR RTK Inhibitors for NSCLC Revenue (USD Million), Gross Margin and Market Share (2019-2021)

Table 98. RPG Life Sciences Corporate Information, Head Office, and Major Competitors

Table 99. RPG Life Sciences Major Business

Table 100. RPG Life Sciences Targeted Drug EGFR RTK Inhibitors for NSCLC Product and Solutions

Table 101. RPG Life Sciences Targeted Drug EGFR RTK Inhibitors for NSCLC Revenue (USD Million), Gross Margin and Market Share (2019-2021)

Table 102. Fresenius Kabi India Corporate Information, Head Office, and Major Competitors

Table 103. Fresenius Kabi India Major Business

Table 104. Fresenius Kabi India Targeted Drug EGFR RTK Inhibitors for NSCLC Product and Solutions

Table 105. Fresenius Kabi India Targeted Drug EGFR RTK Inhibitors for NSCLC Revenue (USD Million), Gross Margin and Market Share (2019-2021)

Table 106. Global Targeted Drug EGFR RTK Inhibitors for NSCLC Revenue (USD Million) by Players (2019-2021)

Table 107. Global Targeted Drug EGFR RTK Inhibitors for NSCLC Revenue Share by Players (2019-2021)

Table 108. Breakdown of Targeted Drug EGFR RTK Inhibitors for NSCLC by Company Type (Tier 1, Tier 2 and Tier 3)

Table 109. Targeted Drug EGFR RTK Inhibitors for NSCLC Players Head Office, Products and Services Provided

Table 110. Targeted Drug EGFR RTK Inhibitors for NSCLC Mergers & Acquisitions in the Past Five Years

Table 111. Targeted Drug EGFR RTK Inhibitors for NSCLC New Entrants and Expansion Plans

Table 112. Global Targeted Drug EGFR RTK Inhibitors for NSCLC Revenue (USD Million) by Type (2016-2021)

Table 113. Global Targeted Drug EGFR RTK Inhibitors for NSCLC Revenue Share by Type (2016-2021)

Table 114. Global Targeted Drug EGFR RTK Inhibitors for NSCLC Revenue Forecast by Type (2021-2026)

Table 115. Global Targeted Drug EGFR RTK Inhibitors for NSCLC Revenue by Application (2016-2021)

Table 116. Global Targeted Drug EGFR RTK Inhibitors for NSCLC Revenue Forecast by Application (2021-2026)

Table 117. North America Targeted Drug EGFR RTK Inhibitors for NSCLC Revenue by Type (2016-2021) & (USD Million)

Table 118. North America Targeted Drug EGFR RTK Inhibitors for NSCLC Revenue by Type (2021-2026) & (USD Million)

Table 119. North America Targeted Drug EGFR RTK Inhibitors for NSCLC Revenue by Application (2016-2021) & (USD Million)

Table 120. North America Targeted Drug EGFR RTK Inhibitors for NSCLC Revenue by Application (2021-2026) & (USD Million)

Table 121. North America Targeted Drug EGFR RTK Inhibitors for NSCLC Revenue by Country (2016-2021) & (USD Million)

Table 122. North America Targeted Drug EGFR RTK Inhibitors for NSCLC Revenue by Country (2021-2026) & (USD Million)

Table 123. Europe Targeted Drug EGFR RTK Inhibitors for NSCLC Revenue by Type (2016-2021) & (USD Million)

Table 124. Europe Targeted Drug EGFR RTK Inhibitors for NSCLC Revenue by Type (2021-2026) & (USD Million)

Table 125. Europe Targeted Drug EGFR RTK Inhibitors for NSCLC Revenue by Application (2016-2021) & (USD Million)

Table 126. Europe Targeted Drug EGFR RTK Inhibitors for NSCLC Revenue by Application (2021-2026) & (USD Million)

Table 127. Europe Targeted Drug EGFR RTK Inhibitors for NSCLC Revenue by Country (2016-2021) & (USD Million)

Table 128. Europe Targeted Drug EGFR RTK Inhibitors for NSCLC Revenue by Country (2021-2026) & (USD Million)

Table 129. Asia-Pacific Targeted Drug EGFR RTK Inhibitors for NSCLC Revenue by Type (2016-2021) & (USD Million)

Table 130. Asia-Pacific Targeted Drug EGFR RTK Inhibitors for NSCLC Revenue by Type (2021-2026) & (USD Million)

Table 131. Asia-Pacific Targeted Drug EGFR RTK Inhibitors for NSCLC Revenue by Application (2016-2021) & (USD Million)

Table 132. Asia-Pacific Targeted Drug EGFR RTK Inhibitors for NSCLC Revenue by Application (2021-2026) & (USD Million)

Table 133. Asia-Pacific Targeted Drug EGFR RTK Inhibitors for NSCLC Revenue by Region (2016-2021) & (USD Million)

Table 134. Asia-Pacific Targeted Drug EGFR RTK Inhibitors for NSCLC Revenue by Region (2021-2026) & (USD Million)

Table 135. South America Targeted Drug EGFR RTK Inhibitors for NSCLC Revenue by Type (2016-2021) & (USD Million)

Table 136. South America Targeted Drug EGFR RTK Inhibitors for NSCLC Revenue by Type (2021-2026) & (USD Million)

Table 137. South America Targeted Drug EGFR RTK Inhibitors for NSCLC Revenue by Application (2016-2021) & (USD Million)

Table 138. South America Targeted Drug EGFR RTK Inhibitors for NSCLC Revenue by Application (2021-2026) & (USD Million)

Table 139. South America Targeted Drug EGFR RTK Inhibitors for NSCLC Revenue by Country (2016-2021) & (USD Million)

Table 140. South America Targeted Drug EGFR RTK Inhibitors for NSCLC Revenue by Country (2021-2026) & (USD Million)

Table 141. Middle East & Africa Targeted Drug EGFR RTK Inhibitors for NSCLC Revenue by Type (2016-2021) & (USD Million)

Table 142. Middle East & Africa Targeted Drug EGFR RTK Inhibitors for NSCLC Revenue by Type (2021-2026) & (USD Million)

Table 143. Middle East & Africa Targeted Drug EGFR RTK Inhibitors for NSCLC Revenue by Application (2016-2021) & (USD Million)

Table 144. Middle East & Africa Targeted Drug EGFR RTK Inhibitors for NSCLC Revenue by Application (2021-2026) & (USD Million)

Table 145. Middle East & Africa Targeted Drug EGFR RTK Inhibitors for NSCLC Revenue by Country (2016-2021) & (USD Million)

Table 146. Middle East & Africa Targeted Drug EGFR RTK Inhibitors for NSCLC Revenue by Country (2021-2026) & (USD Million)

List of Figures

Figure 1. Targeted Drug EGFR RTK Inhibitors for NSCLC Picture

Figure 2. Global Targeted Drug EGFR RTK Inhibitors for NSCLC Revenue Market Share by Type in 2020

Figure 3. Icotinib

Figure 4. Gefitinib

Figure 5. Erlotinib

Figure 6. Afatinib

Figure 7. Osimertinib

Figure 8. Brigatinib

Figure 9. Other

Figure 10. Targeted Drug EGFR RTK Inhibitors for NSCLC Revenue Market Share by Application in 2020

Figure 11. Squamous Cell Carcinoma of NSCLC Picture

Figure 12. Adenocarcinoma of NSCLC Picture

Figure 13. Large Cell Carcinoma of NSCLC Picture

Figure 14. Global Targeted Drug EGFR RTK Inhibitors for NSCLC Revenue, (USD Million): 2020 VS 2021 VS 2026

Figure 15. Global Targeted Drug EGFR RTK Inhibitors for NSCLC Revenue and Forecast (2016-2026) & (USD Million)

Figure 16. Global Targeted Drug EGFR RTK Inhibitors for NSCLC Revenue Market Share by Region (2016-2026)

Figure 17. Global Targeted Drug EGFR RTK Inhibitors for NSCLC Revenue Market Share by Region in 2020

Figure 18. North America Targeted Drug EGFR RTK Inhibitors for NSCLC Revenue (USD Million) and Growth Rate (2016-2026)

Figure 19. Europe Targeted Drug EGFR RTK Inhibitors for NSCLC Revenue (USD Million) and Growth Rate (2016-2026)

Figure 20. Asia-Pacific Targeted Drug EGFR RTK Inhibitors for NSCLC Revenue (USD Million) and Growth Rate (2016-2026)

Figure 21. South America Targeted Drug EGFR RTK Inhibitors for NSCLC Revenue (USD Million) and Growth Rate (2016-2026)

Figure 22. Middle East and Africa Targeted Drug EGFR RTK Inhibitors for NSCLC Revenue (USD Million) and Growth Rate (2016-2026)

Figure 23. Targeted Drug EGFR RTK Inhibitors for NSCLC Market Drivers

Figure 24. Targeted Drug EGFR RTK Inhibitors for NSCLC Market Restraints

Figure 25. Targeted Drug EGFR RTK Inhibitors for NSCLC Market Trends

Figure 26. Beta Pharma Recent Developments and Future Plans

Figure 27. AstraZeneca Recent Developments and Future Plans

Figure 28. Natco Pharma Recent Developments and Future Plans

Figure 29. Qilu Pharmaceutical Recent Developments and Future Plans

Figure 30. Genentech (Roche Group) Recent Developments and Future Plans

Figure 31. Mylan Recent Developments and Future Plans

Figure 32. Teva Recent Developments and Future Plans

Figure 33. OSI Pharmaceuticals Recent Developments and Future Plans

Figure 34. Glenmark Pharmaceuticals Recent Developments and Future Plans

Figure 35. Beacon Pharmaceuticals Recent Developments and Future Plans

Figure 36. Boehringer Ingelheim Recent Developments and Future Plans

Figure 37. Pfizer Recent Developments and Future Plans

Figure 38. ARIAD Pharmaceuticals (Takeda) Recent Developments and Future Plans

Figure 39. Genvio Pharma Limited Recent Developments and Future Plans

Figure 40. Drug International Limted Recent Developments and Future Plans

Figure 41. Everest Pharmaceuticals Recent Developments and Future Plans

Figure 42. Incepta Pharmaceuticals Limited Recent Developments and Future Plans

Figure 43. Cipla Pharma Recent Developments and Future Plans

Figure 44. Dr Reddy's Laboratories Recent Developments and Future Plans

Figure 45. Zydus Cadila Recent Developments and Future Plans

Figure 46. Hetero Drugs Recent Developments and Future Plans

Figure 47. Intas Pharmaceuticals Recent Developments and Future Plans

Figure 48. Alkem Laboratories Recent Developments and Future Plans

Figure 49. RPG Life Sciences Recent Developments and Future Plans

Figure 50. Fresenius Kabi India Recent Developments and Future Plans

Figure 51. Global Targeted Drug EGFR RTK Inhibitors for NSCLC Revenue Share by Players in 2020

Figure 52. Targeted Drug EGFR RTK Inhibitors for NSCLC Market Share by Company Type (Tier 1, Tier 2 and Tier 3)

Figure 53. Global Top 3 Players Targeted Drug EGFR RTK Inhibitors for NSCLC Revenue Market Share in 2020

Figure 54. Global Top 10 Players Targeted Drug EGFR RTK Inhibitors for NSCLC Revenue Market Share in 2020

Figure 55. Key Players Market Share Trend (Top 3 Market Share: 2019 VS 2020 VS 2021)

Figure 56. Global Targeted Drug EGFR RTK Inhibitors for NSCLC Revenue Share by Type in 2020

Figure 57. Global Targeted Drug EGFR RTK Inhibitors for NSCLC Market Share Forecast by Type (2021-2026)

Figure 58. Global Targeted Drug EGFR RTK Inhibitors for NSCLC Revenue Share by Application in 2020

Figure 59. Global Targeted Drug EGFR RTK Inhibitors for NSCLC Market Share Forecast by Application (2021-2026)

Figure 60. North America Targeted Drug EGFR RTK Inhibitors for NSCLC Sales Market Share by Type (2016-2026)

Figure 61. North America Targeted Drug EGFR RTK Inhibitors for NSCLC Sales Market Share by Application (2016-2026)

Figure 62. North America Targeted Drug EGFR RTK Inhibitors for NSCLC Revenue Market Share by Country (2016-2026)

Figure 63. United States Targeted Drug EGFR RTK Inhibitors for NSCLC Revenue and Growth Rate (2016-2026) & (USD Million)

Figure 64. Canada Targeted Drug EGFR RTK Inhibitors for NSCLC Revenue and Growth Rate (2016-2026) & (USD Million)

Figure 65. Mexico Targeted Drug EGFR RTK Inhibitors for NSCLC Revenue and Growth Rate (2016-2026) & (USD Million)

Figure 66. Europe Targeted Drug EGFR RTK Inhibitors for NSCLC Sales Market Share by Type (2016-2026)

Figure 67. Europe Targeted Drug EGFR RTK Inhibitors for NSCLC Sales Market Share by Application (2016-2026)

Figure 68. Europe Targeted Drug EGFR RTK Inhibitors for NSCLC Revenue Market Share by Country (2016-2026)

Figure 69. Germany Targeted Drug EGFR RTK Inhibitors for NSCLC Revenue and Growth Rate (2016-2026) & (USD Million)

Figure 70. France Targeted Drug EGFR RTK Inhibitors for NSCLC Revenue and Growth Rate (2016-2026) & (USD Million)

Figure 71. United Kingdom Targeted Drug EGFR RTK Inhibitors for NSCLC Revenue and Growth Rate (2016-2026) & (USD Million)

Figure 72. Russia Targeted Drug EGFR RTK Inhibitors for NSCLC Revenue and Growth Rate (2016-2026) & (USD Million)

Figure 73. Italy Targeted Drug EGFR RTK Inhibitors for NSCLC Revenue and Growth Rate (2016-2026) & (USD Million)

Figure 74. Asia-Pacific Targeted Drug EGFR RTK Inhibitors for NSCLC Sales Market Share by Type (2016-2026)

Figure 75. Asia-Pacific Targeted Drug EGFR RTK Inhibitors for NSCLC Sales Market Share by Application (2016-2026)

Figure 76. Asia-Pacific Targeted Drug EGFR RTK Inhibitors for NSCLC Revenue Market Share by Region (2016-2026)

Figure 77. China Targeted Drug EGFR RTK Inhibitors for NSCLC Revenue and Growth Rate (2016-2026) & (USD Million)

Figure 78. Japan Targeted Drug EGFR RTK Inhibitors for NSCLC Revenue and Growth Rate (2016-2026) & (USD Million)

Figure 79. South Korea Targeted Drug EGFR RTK Inhibitors for NSCLC Revenue and Growth Rate (2016-2026) & (USD Million)

Figure 80. India Targeted Drug EGFR RTK Inhibitors for NSCLC Revenue and Growth Rate (2016-2026) & (USD Million)

Figure 81. Southeast Asia Targeted Drug EGFR RTK Inhibitors for NSCLC Revenue and Growth Rate (2016-2026) & (USD Million)

Figure 82. Australia Targeted Drug EGFR RTK Inhibitors for NSCLC Revenue and Growth Rate (2016-2026) & (USD Million)

Figure 83. South America Targeted Drug EGFR RTK Inhibitors for NSCLC Sales Market Share by Type (2016-2026)

Figure 84. South America Targeted Drug EGFR RTK Inhibitors for NSCLC Sales Market Share by Application (2016-2026)

Figure 85. South America Targeted Drug EGFR RTK Inhibitors for NSCLC Revenue Market Share by Country (2016-2026)

Figure 86. Brazil Targeted Drug EGFR RTK Inhibitors for NSCLC Revenue and Growth Rate (2016-2026) & (USD Million)

Figure 87. Argentina Targeted Drug EGFR RTK Inhibitors for NSCLC Revenue and Growth Rate (2016-2026) & (USD Million)

Figure 88. Middle East and Africa Targeted Drug EGFR RTK Inhibitors for NSCLC Sales Market Share by Type (2016-2026)

Figure 89. Middle East and Africa Targeted Drug EGFR RTK Inhibitors for NSCLC Sales Market Share by Application (2016-2026)

Figure 90. Middle East and Africa Targeted Drug EGFR RTK Inhibitors for NSCLC Revenue Market Share by Country (2016-2026)

Figure 91. Turkey Targeted Drug EGFR RTK Inhibitors for NSCLC Revenue and Growth Rate (2016-2026) & (USD Million)

Figure 92. Saudi Arabia Targeted Drug EGFR RTK Inhibitors for NSCLC Revenue and Growth Rate (2016-2026) & (USD Million)

Figure 93. UAE Targeted Drug EGFR RTK Inhibitors for NSCLC Revenue and Growth Rate (2016-2026) & (USD Million)

Figure 94. Methodology

Figure 95. Research Process and Data Source